MSTN and chronic kidney disease: On the other hand, the myostatin signaling pathway is a critical negative regulator of skeletal muscle mass, which is upregulated in skeletal muscle of patients with CKD [41] in response to oxidative stress, inflammation, uremic toxins, angiotensin II, glucocorticoids, and metabolic acidosis in CKD [26,42].